Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials

Journal of Thoracic and Cardiovascular Surgery

Volumn 128, Issue 3, 2004, Pages 442-448

  Sedrakyan, Artyom ^a,b,d   Treasure, Tom ^b,c   Elefteriades, John A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

23; 31

Indexed keywords

ACETYLSALICYLIC ACID; APROTININ;

BLOOD TRANSFUSION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; EMBASE; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INFORMATION PROCESSING; INFORMATION RETRIEVAL; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL ANALYSIS; STROKE; SURGICAL MORTALITY; SYSTEMATIC REVIEW;

EID: 4444380033     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2004.03.041     Document Type: Article

References (22)

1. Alderman E.L., Levy J.H., Rich J.B., Nili M., Vidne B., Schaff H., et al. Analyses of coronary graft patency after aprotinin use results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg. 116:1998;716-730
2. Levy J.H., Pifarre R., Schaff H.V., Horrow J.C., Albus R., Spiess B., et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 92:1995;2236-2244
3. Lemmer J.H., Dilling E.W., Morton J.R., Rich J.B., Robicsek F., Bricker D.L., et al. Aprotinin for primary coronary artery bypass grafting a multicenter trial of three dose regimens. Ann Thorac Surg. 62:1996;1659-1668
4. Cosgrove D.M., Heric B., Lytle B.W., Taylor P.C., Novoa R., Golding L.A., et al. Aprotinin therapy for reoperative myocardial revascularization a placebo-controlled study. Ann Thorac Surg. 54:1992;1031-1036
5. Smith P.K., Muhlbaier L.H. Aprotinin safe and effective only with the full-dose regimen. Ann Thorac Surg. 62:1996;1575-1577
6. Mangano D.T. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 347:2002;1309-1317
7. Levi M., Cromheecke M.E., de Jonge E., Prins M.H., de Mol B.J., Briet E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery a meta-analysis of clinically relevant endpoints. Lancet. 354:1999;1940-1947
8. Frumento R.J., O'Malley C.M., Bennett-Guerrero E. Stroke after cardiac surgery a retrospective analysis of the effect of aprotinin dosing regimens. Ann Thorac Surg. 75:2003;479-483
9. Olivencia-Yurvati A.H., Wallace W.E., Wallace N., Dimitrijevich D., Knust J.K., Haas L., et al. Intraoperative treatment strategy to reduce the incidence of postcardiopulmonary bypass atrial fibrillation. Perfusion. 17:(Suppl):2002;35-39
10. Weightman W.M., Gibbs N.M. Pharmacological strategies for blood loss. [letter] Lancet. 357:2001;1131
11. Blackburn H., Keys A., Simonson E. The electrocardiogram in population studies a classification system. Circulation. 21:1960;1160-1175
12. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials is blinding necessary? Control Clin Trials. 17:1996;1-12
13. Petitti D. Decision analysis and cost-effectiveness analysis methods for quantitative synthesis in medicine. 1994;Oxford University Press, New York
14. Shadish W.R., Haddock C.R. The handbook of research synthesis. 1994;Russell Sage Foundation, New York
15. Hayashida N., Isomura T., Sato T., Maruyama H., Kosuga K., Aoyagi S. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg. 114:1997;261-269
16. Moran S.V., Lema G., Medel J., Irarrazaval M.J., Zalaquett R., Garayar B., et al. Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery. Perfusion. 15:2000;105-110
17. Santamaria A., Mateo J., Oliver A., Litvan H., Murillo J., Souto J.K., et al. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery similar transfusion requirements and blood loss. Haematologica. 85:2000;1277-1284
18. Lemmer J.H., Stanford W., Bonney S.L., Breen J.F., Chomka E.V., Eldredge W.J., et al. Aprotinin for coronary bypass operations efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg. 107:1994;543-551
19. Dietrich W., Dilthey G., Spannagl M., Jochum M., Braun S.L., Richter J.A. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Anesthesiology. 83:1995;679-689. discussion 29A-30A
20. Murkin J.M., Lux J., Shannon N.A., Guiraudon G.M., Menkis A.H., McKenzie F.N., et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg. 107:1994;554-561
21. Royston D. Aprotinin versus lysine analogues the debate continues. Ann Thorac Surg. 65:(4 Suppl):1998;S9-19. discussion S27-8
22. Asimakopoulos G., Kohn A., Stefanou D.C., Haskard D.O., Landis R.C., Taylor K.M. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 69:2000;1192-1197